MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer
-
María Dolores Fenor [1] ; Sergio Ruiz-Llorente [1] ; Juan Francisco Rodríguez-Moreno [1] ; Eduardo Caleiras [2] ; Juan Carlos Torrego [3] ; Elena Sevillano-Fernández [1] ; Paloma Navarro [1] ; Mónica Yagüe-Fernández [1] ; Sandra Amarilla-Quintana [1] ; Arantzazu Barquín [1] ; Jesús García-Donas [1]
-
[1] Hospital Universitario HM Sanchinarro
Hospital Universitario HM Sanchinarro
Madrid, España
-
[2] Centro Nacional de Investigaciones Oncológicas
Centro Nacional de Investigaciones Oncológicas
Madrid, España
-
[3] Servicio Oncología Médica, Hospital Campo Grande, Valladolid, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 12 (December), 2022, págs. 2432-2440
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose The identification of subpopulations harboring druggable targets has become a major step forward in the subclassification of solid tumors into small groups suitable for specific therapies. BRAF fusions represent a paradigm of uncommon and targetable oncogenic events and have been widely correlated to the development of specific malignancies. However, they are only present in a limited frequency across most common tumor types. At this regard, we performed a genomic screening aimed to identifying rare variants associated to advanced prostate cancer development.
Methods Tumoral tissue genomic screening of 41 patients developing advanced prostate cancer was performed at our center as part of the GETHI XX study. The project, sponsored by the Spanish Collaborative Group in Rare Cancers (GETHI), aims to analyze the molecular background of rare tumors and to discover unfrequent molecular variants in common tumors.
Results Here we present the clinical outcome and an in-deep molecular analysis performed in a case harboring a SND1-BRAF fusion gene. The identification of such rearrangement in a patient refractory to standard therapies led to the administration of trametinib (MEK inhibitor). Despite unsensitive to standard therapies, the patient achieved a dramatic response to trametinib. A comprehensive study of the tumor demonstrated this event to be a trunk alteration with higher expression of MEK in areas of tumor invasion.
Conclusions Our study describes the patient-driven discovery of the first BRAF fusion-driven prostate cancer effectively treated with trametinib. Consequently, MAPK pathway activation could define a new subtype of prostate cancer susceptible to a tailored management.
